Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424759 | 0.84 | HRH4 (0.46) | HRH4NMT1HRH3EGFRFGFR1 | |
| SCHEMBL3425233 | 0.80 | HRH4 (0.42) | HRH4NPY1RNMT1HRH3EGFR | |
| SCHEMBL1625904 | 0.78 | KDM4E (0.41) | HRH4NPY1RNMT1HRH3GPR119 | |
| SCHEMBL1625928 | 0.77 | HSD11B1 (0.44) | HRH4HRH3SIGMAR1ABL1SRC | |
| SCHEMBL3425503 | 0.76 | HRH4 (0.44) | HRH4NPY1RNMT1HRH3SLC6A4 | |
| SCHEMBL603718 | 0.76 | NPY5R (0.44) | HRH4NPY1RHRH3 | |
| SCHEMBL11484202 | 0.76 | HRH3 (0.51) | HRH3KCNH2SIGMAR1 | |
| SCHEMBL17339936 | 0.75 | FPR2 (0.57) | HRH3FPR2PROKR1 | |
| SCHEMBL11483805 | 0.75 | HRH3 (0.54) | HRH3KCNH2 | |
| SCHEMBL11484935 | 0.75 | HRH3 (0.54) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723527-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723526-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723359-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7705149-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705143-B2 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-[1,4]diazepan-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA N.V. (BG) | 2010-04-27 | — | — | US | disclosed |
| US-7662966-B2 | For example, 5-tert-Butyl-2-{2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20090281307-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-12 | — | — | US | disclosed |
| US-20090275748-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-05 | — | — | US | disclosed |
| US-20090270613-A1 | Benzoimidazole compounds | EDWARDS JAMES P | 2009-10-29 | — | — | US | disclosed |
| US-20090270611-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270366-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090264646-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264645-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090247508-A1 | Benzoimidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
| EP-1673348-B1 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270613-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20090264646-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20090270366-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20090270611-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20090275748-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 872/4885NMT1 3065/4885 |
| US-20090247508-A1 | Benzoimidazole Compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20090264645-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
| US-20090281307-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HRH4 1/4885NPY1R 1328/4885NMT1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.